Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessEnovis Initiated With Buy Rating at UBS

Enovis Initiated With Buy Rating at UBS

Add to Favorite
Added to Favorite


UBS analysts initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a price target of $75.00. The analysts anticipate that Enovis will lead the orthopedics market with high single-digit sales growth through at least 2027, driven by a shift in its portfolio mix towards higher-growth and higher-margin Reconstructive (Recon) products.
Key factors contributing to Enovis’s potential sales and EPS growth include the acquisition of LimaCorporate, which not only enhances exposure to the growing Recon sector but also improves margins.
Additionally, opportunities for international cross-selling, greater than expected market share gains in extremities, effective execution of new product launches, and stronger growth in the Prevention & Recovery (P&R) segment are expected. The latter is underpinned by a stable supply chain and increasing pricing power.

Subscribe to get Latest News Updates

Latest News

You may like more
more

3M Upgraded to Strong Buy as Strategic Overhaul Signals Growth Potential

CFRA analysts upgraded 3M (NYSE:MMM) to Strong Buy from...

UnitedHealth Group Added to Analyst Favorites List at Raymond James Amid Attractive Valuation

Raymond James added UnitedHealth Group (NYSE:UNH) to its Analyst...

ACV Auctions Gains 2 percent as Needham Boosts Price Target to $28

ACV Auctions Inc. (NASDAQ:ACVA) shares rose more than 2%...